AI evidence summary · MVP
Bacopa Monnieri for Cognitive Function
AI preliminary evidence assessment
CC 級|AI 整體初步評級
This preliminary assessment is currently available in Traditional Chinese.
Exact question無失智成人口服單方假馬齒莧萃取物,相較安慰劑或相同背景照護,能改善記憶、注意力或反應速度嗎?有哪些不良反應?
部分記憶測驗呈正向結果,但注意力與反應速度結果不一致;十二週及近期試驗的陰性結果保留,來源受限的急性陰性報告亦作脈絡。現有證據不能支持全面認知改善,也不能外推為失智預防。
Additional assessment reasons await presentation; see the research results below.
Limitations affecting this assessment
- 獨立交叉評讀將本題標記為 U,僅作交叉核對;整體 C 由完整原評分流程產生。這些類別不是正式 GRADE 或療效機率。
- 檢索限於有界 PubMed 搜尋,並非全球完整系統性回顧;部分全文未取得,另有一筆僅有書目資料的未決報告,不增加效益證據。
- 讀者摘要涵蓋九份直接及六份來源受限報告;三份回顧不增加獨立支持票,另九十八筆已篩選背景文獻未生成讀者摘要。來源受限報告不列直接效益票:急性陰性報告的成人年齡資格未核實,兩份 CDRI 08 急性報告可能同一試驗,Erratum 未取得內文且不算新試驗。
- 九個直接研究可依方案、地點、族群或時間區分事件,但不證明所有受試者個體零重疊。試驗臂、重複測驗、交叉期別、分析子樣本與回顧人數不另算獨立證據。
- 摘要來源無法完整核對分派隱蔽、多重比較、分析集、退出原因、傷害分母及資助/利益衝突;流程未明者不推定為隨機或完成,未報安全結果不等於沒有傷害。
- 年齡、健康或主觀記憶困難族群、萃取物與療程不同,不能視為同質;38538390 的成人/無失智資格及總認知結果仍未解決。
- 多個測驗及時點、部分完成者分析、失訪和小樣本降低確定性。組內顯著而另一組不顯著,本身不等於組間差異;測驗顯著也不直接證明日常功能改善。
- 沒有支持失智預防的直接終點;ERP、血中 AChE、BDNF 等替代指標不增加獨立臨床效益票。
- 記憶、注意力與反應速度分開解讀,急性與長期補充亦分開。部分記憶測驗呈正向結果,但注意力與速度不一致,不能概括為全面認知改善。
- 20703343 原文排除 MMSE >24 者,與無失智資格說法衝突;保留原印刷記載,不更改不等號或推定作者原意。
- 本次外部證據資料庫資料缺失,系統性回顧也未被納入該計分欄位;兩個欄位各依原規則採0.5中性政策值。這些值不是研究支持票,也不表示文獻中沒有系統性回顧。
- 保留十二週 450 mg 研究的認知組間陰性結果,以及近期研究主要言語學習、注意力、工作記憶陰性結果;來源受限的急性陰性報告另作脈絡。
- 近期研究假馬齒莧組自述不良反應較多,主要為消化道不適與頭痛;其他來源亦報告腸胃症狀及一例與藥物關係不確定的皮疹退出。
- 高齡試驗的41件總不良事件及19件可能相關事件是事件數,不是發生不良反應的人數,不可計算受試者發生率。
- 認知訓練試驗兩組背景訓練相同,屬隨機加用設計;反應較慢及未顯著的準確率差異只支持速度與準確度取捨的假說。未校正探索性影像結果不代表臨床效益。
Research results
Findings are currently provided in Traditional Chinese; source excerpts retain their original language.
Main result 1
約12週治療記憶:新資訊保留測驗有顯著效果,學習速率未改善,作者解讀為遺忘較慢;言語與視覺短期記憶、既有知識提取及日常記憶問卷未改善。注意力:未改善。反應時間:摘要未提供結果。
Applicability assessment: 報告七十六名40至65歲成人;參與流程角色未明。來源未交代失智排除方法。
- Population
- 報告七十六名40至65歲成人,參與流程角色未明
- Intervention
- 假馬齒莧(Brahmi)
- Comparator
- 安慰劑
- Outcome
- 新資訊保留有顯著效果;學習速率、注意力、短期記憶及日常記憶問卷未見改善
- Follow-up
- 約12週治療
- Formulation
- Not established
- Dose
- 摘要未報告
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 2
治療12週記憶:延遲回憶呈改善訊號,即時回憶與字數工作記憶未顯著改善。注意力:分配注意力的閾值及準確率無顯著效果。反應時間:Stroop幹擾時間改善。主要記憶與Stroop分析多採各組內時間趨勢,不能僅以一組顯著、另一組不顯著證明單項組間優越性;跨多項結果的綜合交互作用提供整體訊號,仍無法取代各領域明確效應。
Applicability assessment: 54名65歲以上、無臨床失智徵象的參與者獲隨機分派。
- Population
- 54名65歲以上、無臨床失智徵象者獲隨機分派
- Intervention
- 口服標準化假馬齒莧萃取物300 mg/日
- Comparator
- 安慰劑
- Outcome
- 延遲詞語回憶:假馬齒莧組的組內時間趨勢顯著,安慰劑組未顯著;不能僅據此斷言單項組間優越性
- Follow-up
- 治療12週
- Formulation
- Not established
- Dose
- 標準化乾燥萃取物300 mg/day,口服12週
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 3
12週記憶:AVLT言語學習、記憶取得及延遲回憶呈顯著組間改善;複雜圖形視覺記憶與主觀記憶問卷沒有顯著組間差異。注意力/處理速度:Trail Making Test沒有顯著組間差異。未提供可獨立判讀的反應時間結果。
Applicability assessment: 98名55歲以上健康參與者獲招募;來源另稱81人完成。
- Population
- 98名55歲以上健康參與者獲招募
- Intervention
- 假馬齒莧BacoMind萃取物300 mg/日
- Comparator
- 相同安慰劑
- Outcome
- AVLT言語學習、記憶取得及延遲回憶改善;CFT、MAC-Q與TMT未見顯著組間差異
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- BacoMind萃取物300 mg/day
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 4
治療12週記憶:邏輯記憶、配對聯想學習及總記憶分數報告較安慰劑改善。注意力:mental control呈正向結果,但digit forward組間差異不顯著;digit backward與視覺再現未顯著變化。反應時間:沒有可擷取結果。停藥後四週分數維持不代表長期疾病預防。
Applicability assessment: 四十名有年齡相關記憶困難者獲隨機分派;來源稱無失智,卻記載排除MMSE大於二十四分者,適用性存疑。
- Population
- 40名年齡相關記憶障礙者獲隨機分派
- Intervention
- 標準化假馬齒莧萃取物125 mg、每日兩次
- Comparator
- 安慰劑
- Outcome
- 第8週及第12週的配對聯想學習報告優於安慰劑
- Follow-up
- 治療12週
- Formulation
- Not established
- Dose
- 標準化萃取物125 mg,每日兩次;總量250 mg/day,bacoside含量55%
Source excerpt: The between group comparison also showed significant improvement on paired associate learning with SBME than placebo after 8 and 12 weeks of drug administration.View source
Main result 5
治療12週記憶:300 mg組工作記憶準確度呈改善,兩劑量部分時間點的記憶反應速度呈正向結果。注意力:注意力持續性與以反應時間構成的注意力指標部分改善。反應時間效果依劑量及時間點而異,未建立一致劑量反應。N100/P300潛時與AChE變化僅為輔助標記,不另算臨床效益。
Applicability assessment: 60名健康高齡志願者參與同一項三組試驗。
- Population
- 60名健康高齡志願者獲招募
- Intervention
- 標準化假馬齒莧萃取物300或600 mg/日
- Comparator
- 安慰劑
- Outcome
- 300 mg組在第4週的注意力持續性及記憶品質優於安慰劑
- Follow-up
- 治療12週
- Formulation
- Not established
- Dose
- 標準化萃取物300或600 mg/day,每日一次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 6
12週記憶/學習、注意力與幹擾、資訊處理/inspection time均未見顯著組間差異。狀態焦慮較低僅為趨勢,不改變主要認知無顯著效果的判讀;未另提供反應時間的數值結果。
Applicability assessment: 報告72名35至60歲健康都市成人;參與流程角色未明。
- Population
- 報告72名35至60歲健康都市成人,參與流程角色未明
- Intervention
- 假馬齒莧萃取物450 mg/日
- Comparator
- 安慰劑
- Outcome
- 各項認知測量均未見顯著組間差異
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- 萃取物450 mg/day,單次每日劑量
Source excerpt: In the present study, there were no significant differences between the two groups on any of the cognitive measures.View source
Main result 7
6週記憶:digit span backwards與邏輯記憶有顯著組間差異,其他記憶測驗未顯著改善。注意力:digit span forwards的組內改善未形成顯著組間差異。反應時間:簡單、選擇、選擇辨識及其他電腦測驗未呈顯著優勢,不能概括為速度改善。
Applicability assessment: 六十名十九至二十二歲醫學生獲納入;結果不宜直接延伸至一般中高齡成人。
- Population
- 60名醫學生獲納入
- Intervention
- 口服標準化假馬齒莧萃取物150 mg、每日兩次
- Comparator
- 匹配安慰劑
- Outcome
- 倒背數字廣度與邏輯記憶測驗報告優於安慰劑
- Follow-up
- 6週
- Formulation
- Not established
- Dose
- Bacognize標準化萃取物150 mg,每日兩次;總量300 mg/day
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 8
12週記憶與注意力準確度未見顯著額外改善。反應時間:假馬齒莧組部分測驗較慢,圖像辨識反應時間增加;空間工作記憶反應時間在安慰劑組變快、假馬齒莧組無變化。準確度平均較高但差異不顯著,因此速度與準確度取捨僅為假說。影像經多重比較校正後無顯著組間差異,未校正探索結果不構成臨床效益。
Applicability assessment: 三十六名健康高齡成人獲隨機分派;兩組均接受相同認知訓練。
- Population
- 36名健康高齡成人獲隨機分派
- Intervention
- 每日服用假馬齒莧CDRI-08萃取物320 mg,並接受認知訓練
- Comparator
- 安慰劑加相同認知訓練
- Outcome
- 假馬齒莧組圖像辨識反應較慢;安慰劑組空間工作記憶反應變快。準確度較高僅為未確證的速度與準確度取捨解釋
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- CDRI-08萃取物160 mg膠囊兩粒,每晨服用;總量320 mg/day
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 9
12週主要認知終點均無顯著組間改善:言語學習p = 0.391、注意力p = 0.713、工作記憶p = 0.610。摘要未單獨提供反應時間結果。壓力與疲勞的部分次要結果改善,不能代替主要認知效益;血液標記亦無組間差異。
Applicability assessment: 101名40至70歲、自述記憶與注意力困難的成人獲隨機分派;摘要未詳述失智篩檢。
- Population
- 101名40至70歲成人獲隨機分派
- Intervention
- 假馬齒莧Bacumen®萃取物300 mg/日
- Comparator
- 安慰劑
- Outcome
- 依87名完成者的資料,言語學習、注意力與工作記憶主要終點均未見顯著組間差異
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- Bacumen萃取物300 mg/day
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 10
於第五週及第十二週測驗摘要描述健康受試者使用假馬齒莧萃取物的長期認知功能研究。
Applicability assessment: 健康受試者的安慰劑對照研究,可提供長期補充的背景資料;此筆僅為來源涵蓋紀錄。
- Population
- 健康人類受試者
- Intervention
- 假馬齒莧萃取物300 mg
- Comparator
- 安慰劑
- Outcome
- 認知功能測驗
- Follow-up
- 於第五週及第十二週測驗
- Formulation
- Not established
- Dose
- Not established
Source excerpt: The current study examined the chronic effects of an extract of B. monniera (Keenmind) on cognitive function in healthy human subjects.View source
Additional finding 11
單次給藥;於二小時後測驗摘要稱單次給藥後各項測驗未見顯著變化。
Applicability assessment: 健康受試者接受單次假馬齒莧或安慰劑,可提供急性給藥研究的背景資料。
- Population
- 健康受試者;假馬齒莧組18人、安慰劑組20人
- Intervention
- 假馬齒莧萃取物300 mg
- Comparator
- 安慰劑
- Outcome
- 認知功能測驗
- Follow-up
- 單次給藥;於二小時後測驗
- Formulation
- Not established
- Dose
- Not established
Source excerpt: No significant changes were found on any of the tests.View source
Safety finding 12
治療12週總共41件不良事件,安慰劑23件、假馬齒莧18件;19件可能相關事件中,安慰劑10件、假馬齒莧9件,來源未發現事件數差異。假馬齒莧可能相關事件常見類流感症狀與消化問題。上述數字全為事件件數,不能視為發生不良反應的人數。
Applicability assessment: 同一項54名無臨床失智徵象高齡者的隨機試驗所報告的不良事件。
- Population
- 54名65歲以上、無臨床失智徵象者獲隨機分派
- Intervention
- 口服標準化假馬齒莧萃取物300 mg/日
- Comparator
- 安慰劑
- Outcome
- 共41件不良事件:安慰劑組23件、假馬齒莧組18件;件數不可當作受影響人數
- Follow-up
- 治療12週
- Formulation
- Not established
- Dose
- 標準化乾燥萃取物300 mg/day,口服12週
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 13
90天摘要記載六十二人完成研究,並接受90天治療後的神經心理測驗。
Applicability assessment: 健康參與者接受假馬齒莧單方萃取物或安慰劑;此筆僅記錄來源涵蓋情形。
- Population
- 健康參與者;一百零七人獲招募,六十二人完成
- Intervention
- 假馬齒莧萃取物KeenMind,每次150 mg、每日兩次
- Comparator
- 安慰劑
- Outcome
- 工作記憶及視覺資訊處理測驗
- Follow-up
- 90天
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 14
12週相較安慰劑報告腸胃副作用,包括排便頻率增加、腹部絞痛與噁心;摘要未提供事件或受影響人數。
Applicability assessment: 同一項招募98名55歲以上健康參與者的試驗所報告的副作用。
- Population
- 98名55歲以上健康參與者獲招募
- Intervention
- 假馬齒莧BacoMind萃取物300 mg/日
- Comparator
- 安慰劑
- Outcome
- 腸胃副作用,包括排便頻率增加、腹部絞痛及噁心;摘要未提供事件或受影響人數
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- BacoMind萃取物300 mg/day
Source excerpt: Bacopa caused GIT side-effects of increased stool frequency, abdominal cramps, and nausea.View source
Safety finding 15
治療12週假馬齒莧組一人因斑丘疹退出;皮疹於第八週報告、持續約15天,報告時已消退,未再挑戰,藥物因果關係難以確立。安慰劑組一人輕度腹瀉、兩人輕度頭痛。臨床與實驗室監測未見藥物相關異常。
Applicability assessment: 同一項四十名年齡相關記憶障礙者獲隨機分派的試驗;其無失智資格記載存在矛盾。
- Population
- 40名年齡相關記憶障礙者獲隨機分派
- Intervention
- 標準化假馬齒莧萃取物125 mg、每日兩次
- Comparator
- 安慰劑
- Outcome
- 假馬齒莧組一名參與者因斑丘疹退出
- Follow-up
- 治療12週
- Formulation
- Not established
- Dose
- 標準化萃取物125 mg,每日兩次;總量250 mg/day,bacoside含量55%
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 16
單次給藥後測驗二十四名健康志願者完成單次給藥後的認知需求測試。
Applicability assessment: 健康志願者接受單次假馬齒莧或安慰劑的交叉研究,提供急性給藥背景。
- Population
- 二十四名健康志願者完成測試
- Intervention
- 假馬齒莧萃取物320 mg或640 mg
- Comparator
- 安慰劑
- Outcome
- 持續認知表現測試
- Follow-up
- 單次給藥後測驗
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 17
治療12週試驗未報告嚴重不良反應,血液、生化與心電圖未見提示毒性的異常,無人退出;未提供輕微事件完整人數或件數,不能推定完全沒有不良反應。
Applicability assessment: 同一項招募60名健康高齡志願者的三組試驗。
- Population
- 60名健康高齡志願者獲招募
- Intervention
- 標準化假馬齒莧萃取物300或600 mg/日
- Comparator
- 安慰劑
- Outcome
- 試驗未顯示與假馬齒莧相關的嚴重不良反應;不能推定沒有輕微事件
- Follow-up
- 治療12週
- Formulation
- Not established
- Dose
- 標準化萃取物300或600 mg/day,每日一次
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 18
單次給藥;於一小時及二小時後測驗十七名健康志願者完成基線及給藥後一、二小時的多工測試。
Applicability assessment: 健康志願者接受單次假馬齒莧或安慰劑的交叉研究,提供急性測試背景。
- Population
- 十七名健康志願者完成測試
- Intervention
- 假馬齒莧萃取物320 mg或640 mg
- Comparator
- 安慰劑
- Outcome
- 多工測試的認知、情緒及壓力相關測量
- Follow-up
- 單次給藥;於一小時及二小時後測驗
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 19
2個月摘要對整體認知表現的結果敘述不一致。
Applicability assessment: 來源研究的是輕度認知障礙患者,與指定的無失智成人問題之適用性需另行確認。
- Population
- 62名輕度認知障礙患者
- Intervention
- 假馬齒莧萃取物160 mg
- Comparator
- 含澱粉粉末的安慰劑
- Outcome
- 整體認知表現與睡眠品質
- Follow-up
- 2個月
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 20
12週未報告嚴重不良反應,但假馬齒莧組自述不良反應頻率顯著較高,主要為消化道不適與頭痛;摘要未提供確切事件數或受影響人數,不能計算絕對風險。
Applicability assessment: 同一項101名40至70歲、自述記憶與注意力困難成人獲隨機分派的試驗。
- Population
- 101名40至70歲成人獲隨機分派
- Intervention
- 假馬齒莧Bacumen®萃取物300 mg/日
- Comparator
- 安慰劑
- Outcome
- 假馬齒莧組自述不良反應較頻繁,主要為消化道不適與頭痛;未報告嚴重不良反應
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- Bacumen萃取物300 mg/day
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSources consulted
- The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Context source; not counted as an included human-result report Abstract only · 2026-10-06T16:18:18.378826Z
- Chronic effects of Brahmi (Bacopa monnieri) on human memory. Abstract only · 2026-10-06T16:18:18.378826Z
- The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Context source; not counted as an included human-result report Abstract only · 2026-10-06T16:18:18.378826Z
- Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. Full text · 2026-10-06T16:18:18.378826Z
- Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Context source; not counted as an included human-result report Abstract only · 2026-10-06T16:18:18.378826Z
- Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. Abstract only · 2026-10-06T16:18:18.378826Z
- Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. Full text · 2026-10-06T16:18:18.378826Z
- An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Context source; not counted as an included human-result report Abstract only · 2026-10-06T16:18:18.378826Z
- Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers. Full text · 2026-10-06T16:18:18.378826Z
- Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults. Abstract only · 2026-10-06T16:18:18.378826Z
- An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Context source; not counted as an included human-result report Abstract only · 2026-10-06T16:18:18.378826Z
- Efficacy of Standardized Extract of Bacopa monnieri (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial. Full text · 2026-10-06T16:18:18.378826Z
- The Neurocognitive Effects of Bacopa monnieri and Cognitive Training on Markers of Brain Microstructure in Healthy Older Adults. Full text · 2026-10-06T16:18:18.378826Z
- Evaluating the effects of Bacopa monnieri on cognitive performance and sleep quality of patients with mild cognitive impairment: A triple-blinded, randomized, placebo-controlled trial. Context source; not counted as an included human-result report Abstract only · 2026-10-06T16:18:18.378826Z
- The Effects of a Bacopa monnieri Extract (Bacumen®) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Abstract only · 2026-10-06T16:18:18.378826Z
Reading and assessment notes
This is an AI preliminary assessment, not expert review or formal GRADE. Read the method and common limitations.
Absence of reported harms does not establish safety. This summary does not provide individual treatment or dosing advice.
Data and assessment record
Search coverage for this case
無失智成人口服單方假馬齒莧萃取物,相較安慰劑或相同背景照護,能改善記憶、注意力或反應速度嗎?有哪些不良反應?
Searched:2026-10-06T16:18:18.378826Z · Databases:PubMed
194 records identified; 194 screened; 9 reports from 9 unique study populations included.
Some included reports were assessed without full text.
- 部分候選文獻未取得全文,完整偏倚風險與次要結果評讀受限。
- 系統檢索限於 PubMed;未涵蓋所有資料庫與完整引文追查。
Processing record
Evidence summary available
Sources through:2026-10-06 · Generated:2026-10-07T07:58:31.732889+00:00
Retrieved 194 records · Screened 194 · Included 9 reports · Omitted 185
Run:verified-v2
codex_cli / gpt-6.1-sol / problem-search-source-bound-l2+l11-v1
{
"included": 9,
"limits_hit": [
"fulltext_unavailable",
"limited_citation_tracing"
],
"omitted": 185,
"retrieved": 194,
"screened": 194
} sha256:83c1ab8f20ebb9b619a8ecbb1bc3d2a1706519b4a32657b4cbdd2021f2bce8e3